Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming

ATNM

Citigroup Initiates Coverage On Gelesis Holdings with Neutral Rating, Announces Price Target of $1.15

By Benzinga Newsdesk

September 20, 7:12 AM

Citigroup analyst Daniel Grosslight initiates coverage on Gelesis Holdings (NYSE:GLS) with a Neutral rating and announces Price Target of $1.15.

GLS

Cumberland Pharmaceuticals Announces New Vibatv Pediatric Publication Highlights Its Safety In Patients 2 To 17 Years Of Age

By Benzinga Newsdesk

October 10, 4:23 PM

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of

CPIX

Argus Research Downgrades Vornado Realty to Hold

Related Posts

Made-In-China Teslas Are The Highest Quality, Says Musk: ‘It Warms My Heart’

Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted For Oral Presentation At The European Hematology Association 2023 Congress

Citigroup Initiates Coverage On Gelesis Holdings with Neutral Rating, Announces Price Target of $1.15

Cumberland Pharmaceuticals Announces New Vibatv Pediatric Publication Highlights Its Safety In Patients 2 To 17 Years Of Age